---
title: Long-Term Efficacy and Safety of Rituximab Versus Tacrolimus in Children With
  Steroid Dependent Nephrotic Syndrome
date: '2023-08-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37547526/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230807180848&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: The superior therapeutic effect of rituximab in SDNS vanishes
  during the second year post-exposure. Rituximab appears to yield longer remission
  when applied as first line as compared to second line therapy. Maintenance MMF following
  rituximab induces long-term disease ...'
disable_comments: true
---
CONCLUSION: The superior therapeutic effect of rituximab in SDNS vanishes during the second year post-exposure. Rituximab appears to yield longer remission when applied as first line as compared to second line therapy. Maintenance MMF following rituximab induces long-term disease ...